Compounds > l 163191
Page last updated: 2024-09-05

l 163191 and at 7519

l 163191 has been researched along with at 7519 in 1 studies

Compound Research Comparison

Studies
(l 163191)		Trials
(l 163191)		Recent Studies (post-2010)
(l 163191)		Studies
(at 7519)		Trials
(at 7519)		Recent Studies (post-2010) (at 7519)
3501727024

Protein Interaction Comparison

ProteinTaxonomyl 163191 (IC50)at 7519 (IC50)
Cyclin-T1Homo sapiens (human)0.0093
Cyclin-dependent kinase 14Homo sapiens (human)0.0198
Cyclin-dependent kinase 1Homo sapiens (human)0.1729
Cyclin-dependent kinase 4Homo sapiens (human)0.0939
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.1682
Cyclin-A2Homo sapiens (human)0.063
G1/S-specific cyclin-D1Homo sapiens (human)0.1168
G1/S-specific cyclin-E1Homo sapiens (human)0.36
Cyclin-dependent kinase 2Homo sapiens (human)0.0586
G1/S-specific cyclin-D3Homo sapiens (human)0.153
Glycogen synthase kinase-3 betaHomo sapiens (human)0.2
Cyclin-dependent kinase 7Homo sapiens (human)2.4
Cyclin-dependent kinase 9Homo sapiens (human)0.0094
Cyclin-HHomo sapiens (human)2.4
CDK-activating kinase assembly factor MAT1Homo sapiens (human)2.4
Cyclin-A1Homo sapiens (human)0.047
Cyclin-dependent kinase 3Homo sapiens (human)0.36
Cyclin-dependent kinase 6Homo sapiens (human)0.1775
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.1393
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.1813
Cyclin-YHomo sapiens (human)0.0198

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1

Other Studies

1 other study(ies) available for l 163191 and at 7519

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013